-
81.发明申请公开(公告)号：US20190375809A1
公开(公告)日：2019-12-12
申请号：US16519959
申请日：2019-07-23
Applicant: Immatics Biotechnologies GmbH
Inventor： Andrea MAHR , Toni WEINSCHENK , Oliver SCHOOR , Jens FRITSCHE , Harpreet SINGH , Claudia WAGNER , Julia LEIBOLD , Colette SONG
IPC: C07K14/47 , C07K14/725 , A61K35/17 , C07K16/28 , C12N5/0783 , C07K14/74 , A61P35/00 , C07K16/30 , G16B20/20 , G01N33/574 , C12Q1/6886 , A61K39/00
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
82.发明申请公开(公告)号：US20190330274A1
公开(公告)日：2019-10-31
申请号：US16457012
申请日：2019-06-28
Applicant: Immatics Biotechnologies GmbH
Inventor： Andrea MAHR , Toni WEINSCHENK , Colette SONG , Oliver SCHOOR , Jens FRITSCHE , Harpreet SINGH
IPC: C07K7/08 , A61K35/17 , G01N33/68 , C07K16/18 , C12N15/115 , A61K39/00 , C07K14/47 , C07K14/725 , C07K7/06
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
83.发明申请公开(公告)号：US20190314476A1
公开(公告)日：2019-10-17
申请号：US16415671
申请日：2019-05-17
Applicant: immatics biotechnologies GmbH
Inventor： Andrea MAHR , Toni WEINSCHENK , Anita WIEBE , Oliver SCHOOR , Jens FRITSCHE , Harpreet SINGH
IPC: A61K39/00 , C07K7/08 , C07K14/47 , C07K14/725 , C07K14/74 , C12N15/115 , C07K16/28 , C07K16/30 , C07K7/06 , C12N5/0783
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
84.发明申请公开(公告)号：US20190314474A1
公开(公告)日：2019-10-17
申请号：US16415552
申请日：2019-05-17
Applicant: Immatics Biotechnologies GmbH
Inventor： Oliver SCHOOR , Andrea MAHR , Toni WEINSCHENK , Anita WIEBE , Jens FRITSCHE , Harpreet SINGH
IPC: A61K39/00 , C12N5/0783 , G01N33/574 , C12Q1/6886 , C12N15/115 , C07K14/47 , C07K16/30 , C07K14/74 , C07K14/705 , C07K14/725
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
公开(公告)号：US20190284256A1
公开(公告)日：2019-09-19
申请号：US16425607
申请日：2019-05-29
Applicant: Immatics biotechnologies GmbH
Inventor： Andrea MAHR , Toni WEINSCHENK , Anita WIEBE , Oliver SCHOOR , Jens FRITSCHE , Harpreet SINGH
IPC: C07K14/74 , A61K39/00 , C12N9/12 , C07K14/47 , C07K7/06 , C07K16/28 , C12N15/115 , C12N5/0783 , G01N33/574 , C12Q1/6886 , G01N33/50 , C07K14/725 , C07K16/30 , C07K7/08
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
Patent Agency Ranking
86.发明申请公开(公告)号：US20190255110A1
公开(公告)日：2019-08-22
申请号：US16274505
申请日：2019-02-13
Applicant: Immatics Biotechnologies GmbH
Inventor： Heiko SCHUSTER , Franziska HOFFGAARD , Jens FRITSCHE , Oliver SCHOOR , Toni WEINSCHENK , Daniel Johannes KOWALEWSKI , Chih-Chiang TSOU
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
87.发明申请公开(公告)号：US20190240305A1
公开(公告)日：2019-08-08
申请号：US16385225
申请日：2019-04-16
Applicant: Immatics Biotechnologies GmbH
Inventor： Andrea MAHR , Toni WEINSCHENK , Oliver SCHOOR , Jens FRITSCHE , Harpreet SINGH , Phillip MUELLER , Julia LEIBOLD , Valentina GOLDFINGER
IPC: A61K39/00 , G01N33/68 , G01N33/574 , C12Q1/6886 , C12N5/0783 , C07K16/30 , C07K14/47 , C12N15/115 , C07K14/725
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
公开(公告)号：US20190218254A1
公开(公告)日：2019-07-18
申请号：US16369905
申请日：2019-03-29
Applicant: IMMATICS BIOTECHNOLOGIES GMBH
Inventor： Toni WEINSCHENK , Steffen WALTER , Jens FRITSCHE , Colette SONG , Harpreet SINGH
CPC classification number: C07K7/08 , A61K38/1709 , A61K39/0011 , C07K7/06 , C12N5/0638 , C12N9/6491 , C12Y304/24065
Abstract: A method of treating a patient who has glioblastoma and/or gastric cancer includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has glioblastoma and/or gastric cancer. A method of treating a patient who has glioblastoma and/or gastric cancer includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the glioblastoma and/or gastric cancer.
-
89.发明申请公开(公告)号：US20190209670A1
公开(公告)日：2019-07-11
申请号：US16367790
申请日：2019-03-28
Applicant: Immatics Biotechnologies GmbH
Inventor： Andrea MAHR , Toni WEINSCHENK , Oliver SCHOOR , Jens FRITSCHE , Harpreet SINGH , Colette SONG
IPC: A61K39/00 , G16B25/00 , A61K35/17 , C07K14/74 , C07K14/47 , C12N15/115 , C12N5/0783 , C07K16/18 , C07K16/30 , C07K16/28
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
90.发明申请公开(公告)号：US20190192571A1
公开(公告)日：2019-06-27
申请号：US16297050
申请日：2019-03-08
Applicant: Immatics Biotechnologies GmbH
Inventor： Andrea MAHR , Toni WEINSCHENK , Anita WIEBE , Colette SONG , Oliver SCHOOR , Jens FRITSCHE , Harpreet SINGH
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
-
-
-
-
-
-
-
-
Search Results
619
records
(took 0.069 seconds)
